Cargando…
Identification of Potential Biomarkers for Liver Cancer Through Gene Mutation and Clinical Characteristics
Liver cancer is a common malignant tumor worldwide, which is a serious threat to the health of people. We try to investigate some mutations and clinical indicators as candidate markers for the development of liver cancer through targeted region capture technology combined with next-generation sequen...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484954/ https://www.ncbi.nlm.nih.gov/pubmed/34604069 http://dx.doi.org/10.3389/fonc.2021.733478 |
_version_ | 1784577434903904256 |
---|---|
author | Cui, Yunlong Li, Hua Zhan, Hongjie Han, Tao Dong, Yixuan Tian, Caijuan Guo, Yixian Yan, Fang Dai, Dong Liu, Pengfei |
author_facet | Cui, Yunlong Li, Hua Zhan, Hongjie Han, Tao Dong, Yixuan Tian, Caijuan Guo, Yixian Yan, Fang Dai, Dong Liu, Pengfei |
author_sort | Cui, Yunlong |
collection | PubMed |
description | Liver cancer is a common malignant tumor worldwide, which is a serious threat to the health of people. We try to investigate some mutations and clinical indicators as candidate markers for the development of liver cancer through targeted region capture technology combined with next-generation sequencing. We collected peripheral blood and liver cancer tissue samples from 32 liver patients concurrently. The SeqCap EZ Prime Choice Probe was used to perform the targeted enrichment; this probe captures 1,000 known cancer-associated genes. We calculated the tumor mutation burden (TMB) for each patient. The high-frequency mutations and these relative genes were identified. Eventually, survival analysis was performed based on the mutations and clinical indicators. In 32 liver patients, a total of 29 high-frequency mutations were investigated. They were located in 25 genes, which were enriched in 9 cellular components (CCs), 6 molecular functions (MFs), and 21 biological processes (BPs). Among them, EZH2 c.1544A>G and CCND1 c.839A>T had the highest mutation frequency (5/32). In the protein–protein interaction (PPI) network, EZH2-DNMT3A, NOTCH1-CCND1, and ABL1-CCND1 were the top three pairs. The survival analysis showed that there were significant differences in progression-free survival (PFS) and overall survival (OS) between the Karnofsky performance score (KPS) groups. The PFS and OS in the TMB high group were higher than those in the TMB low group. OS and tumor stage had a remarkable relationship. In conclusion, EZH2 c.1544A>G and CCND1 c.839A>T might be potential biomarkers of liver cancer. TMB might be used as a prognosis and survival indicator of liver cancer. |
format | Online Article Text |
id | pubmed-8484954 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84849542021-10-02 Identification of Potential Biomarkers for Liver Cancer Through Gene Mutation and Clinical Characteristics Cui, Yunlong Li, Hua Zhan, Hongjie Han, Tao Dong, Yixuan Tian, Caijuan Guo, Yixian Yan, Fang Dai, Dong Liu, Pengfei Front Oncol Oncology Liver cancer is a common malignant tumor worldwide, which is a serious threat to the health of people. We try to investigate some mutations and clinical indicators as candidate markers for the development of liver cancer through targeted region capture technology combined with next-generation sequencing. We collected peripheral blood and liver cancer tissue samples from 32 liver patients concurrently. The SeqCap EZ Prime Choice Probe was used to perform the targeted enrichment; this probe captures 1,000 known cancer-associated genes. We calculated the tumor mutation burden (TMB) for each patient. The high-frequency mutations and these relative genes were identified. Eventually, survival analysis was performed based on the mutations and clinical indicators. In 32 liver patients, a total of 29 high-frequency mutations were investigated. They were located in 25 genes, which were enriched in 9 cellular components (CCs), 6 molecular functions (MFs), and 21 biological processes (BPs). Among them, EZH2 c.1544A>G and CCND1 c.839A>T had the highest mutation frequency (5/32). In the protein–protein interaction (PPI) network, EZH2-DNMT3A, NOTCH1-CCND1, and ABL1-CCND1 were the top three pairs. The survival analysis showed that there were significant differences in progression-free survival (PFS) and overall survival (OS) between the Karnofsky performance score (KPS) groups. The PFS and OS in the TMB high group were higher than those in the TMB low group. OS and tumor stage had a remarkable relationship. In conclusion, EZH2 c.1544A>G and CCND1 c.839A>T might be potential biomarkers of liver cancer. TMB might be used as a prognosis and survival indicator of liver cancer. Frontiers Media S.A. 2021-09-17 /pmc/articles/PMC8484954/ /pubmed/34604069 http://dx.doi.org/10.3389/fonc.2021.733478 Text en Copyright © 2021 Cui, Li, Zhan, Han, Dong, Tian, Guo, Yan, Dai and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Cui, Yunlong Li, Hua Zhan, Hongjie Han, Tao Dong, Yixuan Tian, Caijuan Guo, Yixian Yan, Fang Dai, Dong Liu, Pengfei Identification of Potential Biomarkers for Liver Cancer Through Gene Mutation and Clinical Characteristics |
title | Identification of Potential Biomarkers for Liver Cancer Through Gene Mutation and Clinical Characteristics |
title_full | Identification of Potential Biomarkers for Liver Cancer Through Gene Mutation and Clinical Characteristics |
title_fullStr | Identification of Potential Biomarkers for Liver Cancer Through Gene Mutation and Clinical Characteristics |
title_full_unstemmed | Identification of Potential Biomarkers for Liver Cancer Through Gene Mutation and Clinical Characteristics |
title_short | Identification of Potential Biomarkers for Liver Cancer Through Gene Mutation and Clinical Characteristics |
title_sort | identification of potential biomarkers for liver cancer through gene mutation and clinical characteristics |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484954/ https://www.ncbi.nlm.nih.gov/pubmed/34604069 http://dx.doi.org/10.3389/fonc.2021.733478 |
work_keys_str_mv | AT cuiyunlong identificationofpotentialbiomarkersforlivercancerthroughgenemutationandclinicalcharacteristics AT lihua identificationofpotentialbiomarkersforlivercancerthroughgenemutationandclinicalcharacteristics AT zhanhongjie identificationofpotentialbiomarkersforlivercancerthroughgenemutationandclinicalcharacteristics AT hantao identificationofpotentialbiomarkersforlivercancerthroughgenemutationandclinicalcharacteristics AT dongyixuan identificationofpotentialbiomarkersforlivercancerthroughgenemutationandclinicalcharacteristics AT tiancaijuan identificationofpotentialbiomarkersforlivercancerthroughgenemutationandclinicalcharacteristics AT guoyixian identificationofpotentialbiomarkersforlivercancerthroughgenemutationandclinicalcharacteristics AT yanfang identificationofpotentialbiomarkersforlivercancerthroughgenemutationandclinicalcharacteristics AT daidong identificationofpotentialbiomarkersforlivercancerthroughgenemutationandclinicalcharacteristics AT liupengfei identificationofpotentialbiomarkersforlivercancerthroughgenemutationandclinicalcharacteristics |